Brokers predict that Tandem Diabetes Care, Inc. (NASDAQ: TNDM) will post earnings per share (EPS) of $ 0.10 for the current quarter, according to Zacks. Six analysts have made estimates of Tandem Diabetes Care’s earnings. The lowest EPS estimate is $ 0.03 and the highest is $ 0.13. Tandem Diabetes Care posted earnings of ($ 0.22) per share for the same quarter last year, a positive year-over-year growth rate of 145.5%. The company is expected to release its next results on Thursday April 29th.
On average, analysts expect Tandem Diabetes Care to post annual earnings of $ 0.02 per share for the current year, with EPS estimates ranging between ($ 0.11) and $ 0.27. For the next year, analysts expect earnings of $ 0.53 per share, with EPS estimates ranging between $ 0.16 and $ 0.92. Zacks Investment Research’s EPS averages are an average based on a survey of research firms involved in Tandem Diabetes Care.
Tandem Diabetes Care (NASDAQ: TNDM) last announced its quarterly earnings data on Tuesday, February 23rd. The medical device company reported earnings of $ 0.22 per share for the quarter, beating Thomson Reuters’ consensus estimate of $ 0.12 by $ 0.10. The company had revenue of $ 168.07 million for the quarter, compared to analyst estimates of $ 141.13 million. Tandem Diabetes Care had a negative net margin of 11.10% and a negative return on equity of 10.98%.
Several brokers recently released reports on TNDM. Lake Street Capital raised its target price on shares of Tandem Diabetes Care from USD 137.00 to USD 150.00 and gave the stock a “Buy” rating in a research report on Thursday, February 25th. Zacks Investment Research downgraded Tandem Diabetes Care from a “buy” rating to a “hold” rating and set a price target of $ 101.00 for the company. in a report on Monday March 1st. Oppenheimer confirmed a buy rating for shares of Tandem Diabetes Care in a research report on Wednesday. SVB Leerink lowered its price target for Tandem Diabetes Care from USD 115.00 to USD 95.00 and a “Market Perform” rating for shares in a report on Thursday the company set. Eventually, Wells Fargo & Company downgraded Tandem Diabetes Care from an “overweight” rating to a “balanced” rating and set a price target of $ 105.00 on the stock. in a research report on Tuesday, December 15th. Five analysts have given the share a hold rating and nine have given it a buy rating. The stock currently has a consensus rating of “Buy” and a consensus price target of $ 114.86.
(Display)
The famous income expert and author of Get Rich With Dividends is giving away his ultimate dividend package … for free!
NASDAQ TNDM opened at $ 87.63 on Friday. The company has a leverage ratio of 0.61, a fast rate of 4.94, and a current rate of 5.61. The stock has a market capitalization of $ 5.48 billion, a price to earnings ratio of -108.18, and a beta of 0.31. The company has a 50-day simple moving average of $ 91.71 and a 200-day simple moving average of $ 99.01. Tandem Diabetes Care has a 52-week low of $ 59.45 and a 52-week high of $ 123.74.
In other news, director Kim D. Blickenstaff sold 200,000 shares of Tandem Diabetes Care stock in a transaction that occurred on Tuesday, March 16. The stock was sold at an average price of $ 87.27 for a total transaction of $ 17,454,000.00. In addition, EVP David B. Berger sold 8,646 shares in the company in a transaction that occurred on Thursday, March 11th. The stock sold at an average price of $ 90.22 for a total value of $ 780,042.12. Following the transaction, the executive vice president now directly owns 13,212 shares in the company valued at $ 1,191,986.64. The disclosure for this sale can be found here. 6.00% of the shares are owned by insiders.
Hedge funds have recently increased or decreased their stake in the business. Candriam Luxembourg SCA increased its position in shares of Tandem Diabetes Care by 63.7% in the fourth quarter. Candriam Luxembourg SCA now owns 52,370 shares in the medical device company valued at $ 5,011,000 after purchasing an additional 20,370 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its stake in Tandem Diabetes Care by 31.8% in the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 128,420 shares in the medical device company valued at $ 12,287,000 after acquiring an additional 31,000 shares during the reporting period. Banque Cantonale Vaudoise increased its position in Tandem Diabetes Care by 5.9% in the fourth quarter. Banque Cantonale Vaudoise now owns 2,929 shares in the medical device company valued at $ 281,000 after purchasing an additional 164 shares last quarter. The North Carolina state treasurer increased its stake in Tandem Diabetes Care by 2.3% in the fourth quarter. The North Carolina state treasurer now owns 22,250 shares in the medical device company valued at $ 2,129,000 after purchasing an additional 510 shares during the reporting period. Finally, the Swiss National Bank increased its position in shares of Tandem Diabetes Care by 1.1% in the fourth quarter. The Swiss National Bank now owns 130,800 shares in the medical device company valued at $ 12,515,000 after buying an additional 1,400 shares last quarter. 88.60% of the shares are owned by hedge funds and other institutional investors.
Tandem Diabetes Care company profile
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and markets a variety of products for people with insulin-dependent diabetes in the United States. The company’s flagship is the t: slim X2 insulin delivery system, a pump platform that includes the t: slim X2 pump, the disposable 300-unit insulin cartridge and an infusion set.
Recommended story: what are different types of coverage ratios?
Get a Free Copy of Zacks Research Report on Tandem Diabetes Care (TNDM)
For more information on research offerings from Zacks Investment Research, please visit Zacks.com
This instant message alert was generated through narrative science technology and financial data from MarketBeat to give readers the fastest, most accurate coverage possible. This story has been reviewed by the editorial staff of MarketBeat prior to publication. Please send questions or comments about this story to [email protected]
13 Shares Institutional investors won’t stop buying
University foundations, pension funds, sovereign wealth funds, hedge funds and other institutional investors invest money in a group of 13 elite stocks.
These institutional investors are not easily influenced by hot stocks that are popular with retail investors. You probably won’t see a Tesla or SnapChat in this group, as institutional investors know that these “popular kid” stocks almost always make not great investments. However, on this list you can find some excellent companies backed by real earnings and real fundamentals.
We had to go through every 13D and 13F filings that institutional investors filed with the SEC last quarter to identify these stocks. After reviewing more than 5,000 submissions, we identified 13 companies that institutional investors have still bought. Big money investors put hundreds of millions of dollars in these stocks.
Check out the “13 Stocks Institutional Investors Won’t Stop Buying”.
